ICU Medical Financial Statements (ICUI)
|
|
|
|
Report date
|
|
|
25.02.2022 |
27.02.2023 |
27.02.2024 |
27.02.2025 |
19.02.2026 |
|
07.05.2026 |
|
Currency
|
|
|
USD |
USD |
USD |
USD |
USD |
|
USD |
|
Financial report URL
|
|
|
|
|
|
|
|
|
|
|
|
Revenue, bln rub |
? |
|
1 316 |
2 280 |
2 259 |
2 382 |
2 230 |
|
2 157 |
|
Operating Income, bln rub |
|
|
123.2 |
-42.9 |
22.8 |
43.0 |
107.0 |
|
80.2 |
|
EBITDA, bln rub |
? |
|
223.5 |
191.5 |
253.2 |
43.0 |
326.5 |
|
314.5 |
|
Net profit, bln rub |
? |
|
103.1 |
-74.3 |
-29.7 |
-117.7 |
0.732 |
|
46.3 |
|
|
OCF, bln rub |
? |
|
267.5 |
-62.1 |
166.2 |
204.0 |
179.8 |
|
167.4 |
|
CAPEX, bln rub |
? |
|
81.2 |
99.3 |
93.7 |
79.4 |
88.0 |
|
87.0 |
|
FCF, bln rub |
? |
|
186.4 |
-161.5 |
72.5 |
124.7 |
91.8 |
|
80.4 |
|
Dividend payout, bln rub
|
|
|
0.000 |
0.000 |
0.000 |
0.000 |
0.000 |
|
0.000 |
|
|
Ordinary share dividend yield, %
|
|
|
0.00% |
|
|
0.00% |
0.00% |
|
0.00% |
|
Dividend payout ratio, %
|
|
|
0.00% |
0.00% |
0.00% |
0.00% |
0.00% |
|
0.00% |
|
|
OPEX, bln rub |
|
|
368.2 |
740.7 |
717.0 |
781.8 |
712.7 |
|
704.0 |
|
Cost of production, bln rub |
|
|
824.8 |
1 582 |
1 519 |
1 557 |
1 410 |
|
1 372 |
|
R&D, bln rub |
|
|
47.5 |
93.0 |
85.3 |
88.6 |
87.5 |
|
85.5 |
|
Interest expenses, bln rub |
|
|
0.858 |
70.8 |
102.7 |
106.5 |
105.4 |
|
84.2 |
|
|
Assets, bln rub |
|
|
1 881 |
4 516 |
4 378 |
4 204 |
4 051 |
|
4 014 |
|
Net Assets, bln rub |
? |
|
1 616 |
2 090 |
2 123 |
1 965 |
2 124 |
|
2 112 |
|
Debt, bln rub |
|
|
45.0 |
1 734 |
1 704 |
1 642 |
1 392 |
|
1 341 |
|
Cash, bln rub |
|
|
567.2 |
213.0 |
254.7 |
308.6 |
308.0 |
|
288.3 |
|
Net debt, bln rub |
|
|
-522.2 |
1 521 |
1 449 |
1 333 |
1 084 |
|
1 053 |
|
|
Ordinary share price, rub |
|
|
237.3 |
|
|
155.2 |
142.7 |
|
129.2 |
|
Number of ordinary shares, mln |
|
|
21.2 |
23.9 |
24.1 |
24.4 |
24.6 |
|
24.8 |
|
|
Market cap, bln rub |
|
|
5 033 |
0 |
0 |
3 784 |
3 515 |
|
3 198 |
|
EV, bln rub |
? |
|
4 511 |
1 521 |
1 449 |
5 117 |
4 600 |
|
4 251 |
|
Book value, bln rub |
|
|
1 384 |
-342 |
-220 |
-208 |
-9 |
|
27 |
|
|
EPS, rub |
? |
|
4.86 |
-3.11 |
-1.23 |
-4.83 |
0.03 |
|
1.87 |
|
FCF/share, rub |
|
|
8.79 |
-6.76 |
3.01 |
5.11 |
3.73 |
|
3.25 |
|
BV/share, rub |
|
|
65.3 |
-14.3 |
-9.12 |
-8.54 |
-0.39 |
|
1.11 |
|
|
EBITDA margin, % |
? |
|
17.0% |
8.40% |
11.2% |
1.80% |
14.6% |
|
14.6% |
|
Net margin, % |
? |
|
7.84% |
-3.26% |
-1.31% |
-4.94% |
0.03% |
|
2.15% |
|
FCF yield, % |
? |
|
3.70% |
|
|
3.29% |
2.61% |
|
2.51% |
|
ROE, % |
? |
|
6.38% |
-3.55% |
-1.40% |
-5.99% |
0.03% |
|
2.19% |
|
ROA, % |
? |
|
5.48% |
-1.65% |
-0.68% |
-2.80% |
0.02% |
|
1.15% |
|
|
P/E |
? |
|
48.8 |
0.00 |
0.00 |
-32.2 |
4 802 |
|
69.0 |
|
P/FCF |
|
|
27.0 |
0.00 |
0.00 |
30.4 |
38.3 |
|
39.8 |
|
P/S |
? |
|
3.82 |
0.00 |
0.00 |
1.59 |
1.58 |
|
1.48 |
|
P/BV |
? |
|
3.64 |
0.00 |
0.00 |
-18.2 |
-370.5 |
|
116.7 |
|
EV/EBITDA |
? |
|
20.2 |
7.94 |
5.72 |
119.1 |
14.1 |
|
13.5 |
|
Debt/EBITDA |
|
|
-2.34 |
7.94 |
5.72 |
31.0 |
3.32 |
|
3.35 |
|
|
R&D/CAPEX, % |
|
|
58.5% |
93.6% |
91.1% |
111.6% |
99.4% |
|
98.2% |
|
|
CAPEX/Revenue, % |
|
|
6.17% |
4.36% |
4.15% |
3.33% |
3.95% |
|
4.04% |
|
| ICU Medical shareholders |
